Epstein Secrets

ion for Research on Equal Opportunity Visiting Fellow Robert Bryce; and GRID Alternatives Policy and Regulatory Manager Alexandra Wyatt; 10:00 AM • House Agriculture subcommittee hybrid hearing on conservation programs - Conservation and Forestry Subcommittee hybrid hearing on 'Challenges and Successes of Conserv

ustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human Rights Commission v

ion for Research on Equal Opportunity Visiting Fellow Robert Bryce; and GRID Alternatives Policy and Regulatory Manager Alexandra Wyatt; 10:00 AM • House Agriculture subcommittee hybrid hearing on conservation programs - Conservation and Forestry Subcommittee hybrid hearing on 'Challenges and Successes of Conse

nsustainable drug prices' concludes - Hybrid hearing on Unsustainable Drug Prices: Testimony from the CEOs (Part II); with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human Rights Commission v

ion for Research on Equal Opportunity Visiting Fellow Robert Bryce; and GRID Alternatives Policy and Regulatory Manager Alexandra Wyatt; 10:00 AM • House Agriculture subcommittee hybrid hearing on conservation programs - Conservation and Forestry Subcommittee hybrid hearing on 'Challenges and Successes of Conse

ustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human Rights Commission v